Bladder metastasis is the spread of a primary tumor from another organ to the bladder. Bladder metastases are rare compared to primary bladder tumors, accounting for <2% of all bladder tumors. Most common sources of metastasis are colorectal cancer (direct invasion), prostate cancer (direct invasion or hematogenous), breast cancer (hematogenous), gastric cancer (peritoneal spread), and melanoma. Routes of spread include: direct invasion (from adjacent pelvic organs), hematogenous, lymphatic, and peritoneal implantation. Clinically may present with hematuria, urinary obstruction, and pelvic pain. On imaging, it may appear as focal or multifocal wall thickening, polypoid mass, or diffuse infiltration. Known primary malignancy history is critical for diagnosis.
Age Range
40-85
Peak Age
65
Gender
Equal
Prevalence
Uncommon
Pathophysiology of bladder metastases depends on the route of spread. Direct invasion is the most common route: direct infiltration of colorectal, prostate, cervical, or uterine tumors into the bladder wall. Hematogenous spread is the second most common: tumor cells from the primary tumor reach capillaries in the bladder wall through blood and form metastatic foci. Breast and melanoma metastases typically arrive hematogenously. Lymphatic spread occurs via the pelvic lymph node chain. Peritoneal implantation occurs when tumors with peritoneal spread such as gastric or ovarian cancer implant on the bladder serosa. On imaging, the enhancement pattern of metastatic tumor reflects histological characteristics of the primary tumor — hypervascular primary tumors (RCC, melanoma) produce hypervascular bladder metastasis while hypovascular tumors (colorectal) show less enhancing metastasis. Hematogenous metastases are usually submucosal and elevate the mucosa; direct invasion may involve all layers of the bladder wall and obliterate the fat plane between perivesical fat and bladder.
Newly developing focal or diffuse thickening of the bladder wall in the context of known primary malignancy, especially with perivesical fat plane obliteration, strongly suggests metastatic involvement.
Focal irregular wall thickening or polypoid mass in the bladder wall in portal venous phase — enhancement pattern depends on primary tumor. In direct invasion, fat plane loss between adjacent organ tumor and bladder wall is seen. Perivesical fat stranding may accompany. Multifocal involvement suggests hematogenous spread.
Report Sentence
Focal irregular thickening of the bladder wall with perivesical fat plane obliteration is observed, consistent with metastatic invasion in the context of known primary malignancy.
Metastatic mass in the bladder wall shows variable signal on T2-weighted images — depending on primary tumor histology. Colorectal metastasis intermediate signal, melanoma metastasis T1-hyperintense/T2-hypointense due to melanin, breast metastasis intermediate-low signal. Perivesical invasion seen as loss of plane between tumor and bladder wall on T2.
Report Sentence
Mass in the bladder wall shows variable signal characteristics on MRI, consistent with metastatic involvement in context of known primary malignancy.
Diffusion restriction in metastatic mass on DWI — variable degrees depending on primary tumor type. Generally ADC values are low (<1.0 × 10⁻³ mm²/s). DWI is complementary to conventional sequences for detection of small metastatic foci.
Report Sentence
Diffusion restriction in metastatic mass on DWI, consistent with malignant tissue.
Heterogeneous enhancement of metastatic mass on contrast-enhanced MRI — necrotic areas do not enhance, viable tumor tissue enhances. Degree and pattern of enhancement depend on primary tumor. In areas of perivesical invasion, enhancing tumor tissue extends through fat plane into bladder wall.
Report Sentence
Metastatic mass in the bladder wall shows heterogeneous enhancement on contrast-enhanced images.
Irregular-bordered mass with hypoechoic or mixed echogenicity in the bladder wall on B-mode US. In direct invasion, connection between adjacent organ mass and bladder wall may be visible. Variable vascularity on Doppler.
Report Sentence
Irregular-bordered mass in the bladder wall on US; further evaluation with CT/MRI recommended.
Other organ metastases (liver, lung, bone, peritoneum) accompanying bladder involvement — indicates disseminated metastatic disease. Pelvic and retroperitoneal lymphadenopathy commonly accompanies. Primary tumor location and staging should be evaluated.
Report Sentence
Liver and lung metastases accompanying bladder wall thickening are observed, consistent with disseminated metastatic disease.
Criteria
Direct extension of adjacent pelvic organ tumor to bladder wall.
Distinct Features
Fat plane loss between primary tumor and bladder, continuous tumor tissue. Most commonly colorectal, cervical, and prostate origin.
Criteria
Metastasis reaching bladder wall via blood. Primary tumor not adjacent to bladder.
Distinct Features
Submucosal mass, mucosa usually intact, may be multifocal. Breast, melanoma, lung origin typical.
Criteria
Implantation of tumors with peritoneal spread on bladder serosa.
Distinct Features
Nodular thickening of serosal surface at bladder dome. Ascites and peritoneal carcinomatosis accompany. Gastric, ovarian origin typical.
Distinguishing Feature
Primary urothelial carcinoma usually appears as solitary papillary/sessile mass; metastasis often submucosal or diffuse infiltrative. Known malignancy history is critical distinguishing criterion. VI-RADS staging designed for primary carcinoma.
Distinguishing Feature
Lymphoma shows homogeneous mass/thickening with very low ADC (<0.7); metastasis usually heterogeneous. Mucosa intact in lymphoma; may be invaded in metastasis.
Distinguishing Feature
Cystitis shows diffuse wall thickening without mass. Clinically, dysuria, fever, and antibiotic response are distinguishing. No malignancy history.
Distinguishing Feature
Stalk sign and early enhancement pattern in urothelial carcinoma; enhancement pattern depending on primary tumor in metastasis.
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
specialist-referralBladder metastasis is usually part of disseminated metastatic disease and prognosis depends on primary tumor. Treatment integrated into systemic therapy of primary tumor. Palliative TUR or radiotherapy may be applied for local symptom control (hematuria, obstruction). Stent or nephrostomy may be needed for ureteral obstruction. Biopsy important to confirm primary tumor histology and guide treatment planning.
Bladder metastasis usually indicates advanced-stage disease with poor prognosis. It most commonly presents with hematuria. Treatment depends on the type and stage of the primary tumor — may include chemotherapy, radiotherapy, and/or palliative surgery (TURBT). Radical surgery (pelvic exenteration) may be considered for colorectal or cervical cancer with direct invasion. Systemic staging should be performed when bladder metastasis is detected.